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Application of the Polymerase Chain Reaction for Detection of
Minimal Residual Disease of Hematologic Malignancies

Mark S. Roth, MD,* and Valeri H. Terry*

Current induction therapies for acule and chronic leukemias and the lymphomas have achieved
significant complete remission rates. Despite this initial .success, disease recurrence remains a major
problem. Relapse from clinically undetectable residual malignant cells is the most likely mechanism
of recurrence. Of crucial importance to the clinician is the accurate detectitm of residual malignant
cells prior lo clinical relapse. Standard approaches to evaluate for this minimal residual disease
(MRD) allow deiection only when Ihe malignani clone exceeds 1%. Patients in remission, however,
may frequently have residual neoplastic cells that are far helow this level. Recently, several Investigators have adapted the polymerase chain reactiim (PCR) lo delect tumor-specific DNA or
RNA sequences. This approach is highly sensitive (able to detect I malignant cell in 10'' normal cells).
The appli catitm ofthis technique to the study of MRD thus far has heen Umited to tumors in which
specific DNA or RNA sequence data are available. This review describes the appUcation cfPCR to the
detection of MRD in patients with chronic myelogenous leukemia, acute lymphoblastic leukemia, and
follicular .small cleaved cell lymphoma. Because the number of clinical studies and length of followup is limited, detection of MRD hy PCR is at present largely a research tool and the biological
significance of MRD as determined by PCR must await further studies. (Henry Ford Ho.sp Med J
1991:39:l 12-16)

C

urative treatment strategies for the acute leukemias. chronic
myelogenous leukemia (CML), and the lymphomas require eradication ofthe malignant clone of cells with intensive
chemotherapy and/or radiation therapy. Despite a high initial
complete remission rate in many patients with these disorders,
disease recurrence remains a major obstacle. The current belief
holds that these recurrences originate from "the few" malignant
cells that escape induction therapy. Detection ofthis "minimal
residual disease" (MRD), in theory, may therefore provide a
useful method for detecting early preclinical relapses and distinguishing subsets of patients who might benefit from additional
therapies in order to sustain remission (1,2). The approaches
presentiy used to evaluate for MRD, including morphology, cytogenetics, cytofiuorimetric analysis, and Southem blotting, are
in general unable to detect the malignant clone until it exceeds
1% to 15% (2-4). More recentiy, the polymerase chain reaction
(PCR) has been applied to evaiuale for the persistence of tumorspecific DNA and/or RNA sequences, thus improving the sensitivity of detection of MRD for some malignancies (1,5-11). The
clinical significance of minimal residual tumor populations as
determined by this highly sensifive molecular approach remains
to be determined. The focus of this review is to summarize the
current application of PCR in monitoring for MRD following allogeneic bone marrow transplant (BMT) for C M L . In addition,
strategies lo extend this detection assay to other hematologic
malignancies will be discussed.
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PCR: Historical Perspectives
The PCR assay provides an in vitro enzymatic technique for
specific gene amplification and detection. The technique was
first described in 1986 by Mullis and coworkers (6), and the basic principles are outlined in the Figure. In brief, a small amount
of cellular DNA ("template") containing the sequence of interest is mixed with two fianking synthetic oligonucleotide primers, all four deoxynucleotides, and DNA polymerase. The DNA
is then cycled through .sequential steps consisting of 1) dissociation of the DNA strands by melting at high temperatures, 2)
cooling to allow annealing of the primers, and 3) copying from
the target template using DNA polymerase. With each cycle the
number of copies ofthe target sequence approximately doubles.
The overall efficiency of a given PCR reaction is in part determined by the specific primer sequences chosen, the nucleic acid
content of the target template, the quality of the DNA or RNA
sample, and the thermocycling conditions. Following 25 to 35
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Table 1
Clinical Applications of PCR
Heat for s t r a n d s e p a r a t i o n

Diagnosis of Genetic Diseases
Sickle cell anemia
Thalassemias
von Willebrand's disease
Hemophilia A

Anneal primers and
extend with Taq polymerase

Additional c y c l e s

Target
Sequence

=
=

Primers

2nd

ttt

cycle

PGR
product

Detection of Pathogens
Human immunodeficiency virus
Cytomegalovirus
Lyme arthritis
Forensics
Bone Marrow Transplant
HLA-Dr typing
Engraftment analysis
Cancer Diagnosis
Chronic myelogenous leukemia
Follicular lymphomas

Figure—Schematic demonstration of DNA amplification by
PCR. The PCR reaction consists of multiple cycles with thefollowing .sequential steps: 1) dissociation ofthe DNA strands by
melting at high temperatures: 2) cooling to allow annealing of
the selected primers; and 3) in the presence of magnesium, deo.xynucleotides, and the appropriate buffer conditions, extending the primers by copying frcm the target template using Taq
DNA polymerase. With each cycle the newly .synthesized DNA
strands serve as additional template for further primer binding
and DNA .synthesis resuhing in an exponential increase in the
numher qf copies ofthe regions flanked by the piimers (see text).
To adapt this procedure for RNA analysis, a complementary
DNA strand is first synthesized from the RNA template using reverse transcriptase (not shown). The second DNA strand is then
generated with Taq polymerase.

performed in chronic phase, the probability of clinically disease-free survival at 4 years ranges from 55% to 70% (23-25).
Despite this apparent success, disease recurrence remains a major obstacle, with the overall 4-year probability of relapse being
approximately 19%- (23-25). Depletion of marrow T-lymphocytes has been used to abrogate graft versus host disease and to
reduce the morbidity and mortality of BMT; however, some
studies suggest an increased relapse rate with this approach (25).
In unrelated HLA-matched transplants (non-T depleted) performed for CML in chronic phase, the relapse rate appears to be
reduced consistent wilh a more significant graft versus leukemia
effect (26). Eariy detection of residual leukemic cells might provide a useful method for distinguishing subsets of patients who
would benefit from additional posttransplant therapy to sustain
remission. The prevalence of residual Ph' cells post-BMT is uncycles, the target sequence may be amplified as much as 10^known. Routine cytogenetic evaluation (20 to 25 metaphases)
fold to 10^-fold (5,6). The PCR product can then be analyzed by
can exclude the presence of Ph' cells at a frequency of greater
direct visualization on an ethidium bromide-stained agarose gel
than or equal to 12% to 14% (95% confidence limits) (3). South(1). This technique is highly sensitive and has allowed analysis
em blot hybridization is more sensitive. This assay can be used
of trace amounts of DNA derived from even a single hair or sinto detect the molecular rearrangement involving the oncogene cgle human sperm (12,13). Because of the high degree of sensiabl on chromosome 9 and the ber locus on chromosome 22 and
tivity, extreme caution must be observed in sample preparation
is capable of detecting abnormal cells at approximately the 1%
and PCR .setup to avoid contamination with either previously
to 5% level (4). Recentiy, we and others have adapted the PCR
amplified DNA products or plasmid DNA. Appropriate positive
to detect the chimeric bcr/abi RNA transcript unique to Ph'(-i-)
controls for successful performance of the PCR assay and negCML cells (1,8-10). As described above, this assay is signifiative controls to exclude contamination should be performed
cantly more sensitive than previously reported techniques (1).
with each assay. The PCR assay has already proved to be of
PCR amplification of genomic DNA containing the bcr/abl rearenormous importance in basic molecular biology research and
rangement as a general strategy to detect CML cells is less prachas several accepted clinical applications (Table I) (14-22). Betical since the breakpoint occurs at variable positions over a 100
cau,se of the highly sensitive and specific nature of the PCR askilobase region 5' to the c-abi oncogene. Despite this variability
say, evaluation for minimal residual cancer cells following ablative therapy is a logical extension ofthis assay and may offer in- at the DNA level, one of two types of mRNA are transcribed in
Ph' chromosome positive CML cells. This transcript involves
sights into optimizing treatment strategies for many malignant
the junction of exon 2 of abl with either exon 11 or exon III of the
disorders.
ber gene (10). In our initial report, we described the application
of this technique to detect MRD in 16 patients treated for CML
CML as a Model System to Detect MRD
by allogeneic BMT (I). In reconstitution experiments, one CML
cell per 10^ normal mononuclear cells could be detected by diAllogeneic BMT has become an important treatment modalrect agarose gel visualization of a bcr/abl specific band followity for Philadelphia chromosome (Ph') positive CML. For BMT
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Table 2
PCR bcr/abl Detection Post Bone Marrow Transplant
Study
(Reference)

Number of
Patients

T-cell
Depletion

7
4
12
8
16
19
14

0
NA
2
5
8
1 1
0

Morgan et al (27)
Lange et al (30)
Gabert etal (31)
Bartram et al (32)
Roth et al (1)
Sawyers et al (28)
Delfau et al (29)
Total

Time of Study
Post-BMT (months)

Number
Positive

60-84
1-43
3-72
19-77
0.25-24
0.5-45
3-63

0
4
1 1
6
1(1

4
5
40

9(1

Transiently
Positive*

Sensitivityt
1/10'^
1/10*
I/IO'
I/IO'
l/IO*
1/10=
l/IO*-- 10^

•Refers to those studies in which more lhan one time point posl-BMT was available,
tRefers lo the detection of one CML cell admixed with the numberof normal cells as indicaied,
Nole: PCR = polymerase chain reaction, BMT = bone marrow Iransplanl, NA = not available.

ing PCR. In all, bcr/abl message was found in 10 of 16 patients
post-BMT. The ber exon Ill/abl 2 fusion was detected in four patients, the ber exon Il/abI 2 product in four patients, and both in
two patients (I). PCR (-F) bcr/abl was present only transiently in
three pafients and correlated with relap.se in three. One patient
died in clinical remission, while two patients were in clinical remission despite persistence of bcr/abl (-F) cells at 180 days. One
ofthese patients has subsequentiy become bcr/abl (-) at day 450
and the other has clinical disease relapse (unpublished data). Interestingly, all six patients evaluated within the first month postBMT were bcr/abl positive, suggesting either prolonged survival
of "malignant cells" or the elimination of the.se bcr/abl positive
cells by the engrafting immune system. Since we do not know
the number of Ph' (-F) cells that are necessary to reestablish clinical CML, the overall significance of PCR (-b) bcr/abl cells detected in clinically disease-free pafients post-BMT remains to be
determined.
Three studies by other investigators also reported a similar
low frequency of PCR (-b) bcr/abl detecfion following allogeneic BMT (Table 2) (27-29). In most ofthe patients who were
bcr/abl (-F), concomitant cytogenetics were negative (28,29). In
contrast, other investigators using RNA PCR have found differing results (Table 2) (30-32). Gabert et al (31) evaluated patients
from three months to six years after BMT. In their study. I I of
12 patients evaluated had persistently (-F) bcr/abl tran.scripts.
Similarly, Bartram et al (32) reported the detection of bcr/abl by
PCR in six of eight patients while Lange el al (30) found four of
four positive. The reasons for these discordant results are not
clear. While this could represent genuine differences in the patients studied, it might also refiect source of material (blood versus marrow) or assay sensifivity differences. Alternatively, the
differences could reflect the significant problem of sample contamination. In their report on 11 of 12 positive patients, Gabert
et al (31) noted that two of their non-CML patient controls were
PCR (-F) on one occasion. To address these controversies, the
need for a multicenter study to standardize materials has been
suggested (33). More recently, we have completed molecular
analysis on 52 CML patients following allogeneic BMT. Con-
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sistent with our eariier observations, PCR detectable bcr/abl
transcripts were present in 34 of 52 patients (34). Correlation of
bcr/abl transcript detection with clinical outcome is currently
under way but it appears that the ab,sence of detectable signal on
two or more occasions following BMT is associated with a very
low risk of relapse (34).
Preliminary conclusions regarding the utility of PCR to detect
bcr/abl transcripts for CML following allogeneic BMT can be
summarized as follows. First, bcr/abl transcripts are detectable
in many patients post-BMT and may be transient, correlate with
relapse, or on occasion persist with clinical remission. Second,
the consistent finding of bcr/abl transcripts at early time points
(less than 30 days) post-BMT suggests a role for tumor elimination by an engrafting immune system. Third, the absence of detectable bcr/abl transcript on at least two separate occasions following BMT is associated with a very lowriskof relapse. Until
additional patients are evaluated with longer follow-up, however, detection of MRD for CML by PCR should be considered
a research tool with as yet an undetermined prognostic significance.

Follicular Small Cleaved Cell
Non-Hodgkin's Lymphoma
The detection assay for MRD in CML relies on the unique
bcr/abl chimeric mRNA present only in the malignant clone. A
similar well-defined chromosomal marker the t( 14; 18) (q32;q21)
is detected by cytogenetics in approximately 85% of follicular
small cleaved cell lymphomas (7). Remarkably the breakpoints
on both chromosomes in this translocation are focused within
narrowly defined regions of DNA, allowing for the design of
oligonucleotide primers and PCR amplification which will generate a PCR fragment that spans the breakpoint. The PCR product thus generated represents a tumor-specific marker. Using
this PCR approach, Crescenzi and coworkers (7) successfully
identified the subclinical presence of lymphoma cells in all
seven patients examined with follicular lymphoma, including
two in clinical remission. The assay was also used to detect re-
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sidual lymphoma cells persisting in a purged bone iTiarrow. As
with CML, the general use of this assay for detection of MRD
following therapy for follicular lymphomas must await further
study. Moreover, Crescenzi et al also caution that the t(l4;18)
in theory could be present in some normal B-cell precursor cells.

Identification of Other Tumor-Specific
Sequences to Assay for MRD
Specific chromosomal translocations amenable to PCR for
use as markers of MRD are not readily available for most of the
hematologic malignancies. Many ofthe lymphoid malignancies
(acute lymphoblastic leukemia [ALL] and some non-Hodgkin's
lymphomas), however, contain unique monoclonal immunoglobulin (Ig) or T-cell receptor (TCR) genes. Three groups have
independently utilized these unique tumor-specific sequences to
evaluate for MRD in ALL (35-37). Yamada and colleagues (35)
used consensus Ig heavy chain gene variable (V) and joining (J)
segment oligonucleotide primers spanning the diversity (D)
segment to PCR amplify and sequence the specific complementarity-determining region III (CDR-III) from pre B-cell ALLs.
Because of somatic mutation and incorporation of random additional nucleotides, this region provides a "DNA-encoded signature" specific for each B-cell clone. These sequences were then
used to generate diagnostic probes with the ability to hybridize
only to the amplified CDR-111 of leukemic cells from which the
sequences were derived. The threshold of detection of this assay
was 1 leukemic in 100,000 normal cells. By this approach, the
authors reported the detection of MRD in six of eight patients
following induction chemotherapy for childhood ALL (36). By
screening a recombinant CDR-III-containing library, the authors were also able to provide quantitative PCR data as well.
Other siiTiilar approaches to evaluate for minimal residual
ALL cells involve the presence of distinct TCR y and 5 loci
found in acute undifferentiated leukemias and both common
and T-cell ALL (37,38). Again, clonospecific probes have been
generated from tumor unique junctional gene .segments. The general sensitivity ofthis approach also approaches I in 100,000.
Hansen-Hagge and coworkers (37), using incorporaied synthetic restriction sites into their consensus PCR primers, have
further adapted their approach to generate clonospecific PCR
probes without the need for DNA sequencing. They have identified the presence of residual leukemia cells in one ALL patient
11 months after achieving complete remission. As with CML
and the follicular small cleaved cell lymphomas, the clinical implications of these preliminary studies must await further investigation.

Summary and Future Applications
The PCR is a highly sensitive, specific, and rapid technique
useful to detect MRD following standard therapy of some hematologic malignancies. Because of the requirement of a unique tumor-specific DNA or RNA sequence, the application at present
has been limited to the detection of MRD in patients with CML,
ALL, and follicular small cleaved cell lymphoma. Even in these
disorders, the numberof clinical studies and length of follow-up
is limited. Because the technique is still subject to several vari-
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ables and standardized methods between laboratories do not exist, the PCR detection assay is not ready for introduction into
routine clinical laboratory use. The detection of MRD by PCR.
therefore, is at present largely a research tool. In addition, the
precise biological and clinical significance of "residual" small
numbers of leukemic cells as detected by PCR has not yet been
determined. Future strategies to evaluate this significance will
need to incorporate quantitative PCR analysis to determine if a
threshold number of malignant cells are required to reestablish
clinical disease. Eventually, the detection of MRD by PCR
should be helpful in monitoring therapeutic effectiveness and
detecting relapses at early .stages and should offer insights into
the biological significance of circulating "malignant" cells for a
variety of hematologic malignancies.
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